Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy

Abstract

This study was designed to investigate the risk of ovarian failure and the pregnancy outcomes in women treated with intravenous cyclophosphamide (IVCYC) pulse therapy for lupus nephritis. Sixty-seven women with proliferative lupus nephritis were studied. The clinical and laboratory data, SLEDAI and damage indices at IVCYC initiation, doses and numbers of IVCYC pulses, pregnancy and fetal outcomes were evaluated. During a follow-up of 74.4 + 20.6 months, amenorrhea occurred in 25 (37.3%) and was sustained permanently in 10 patients (14.9%). Thirteen women became pregnant with a total of 19 pregnancies. Seventeen pregnancies ended without complications and all babies were born healthy without any congenital anomalies or perinatal illnesses. Two pregnancies were terminated by induced abortion but no congenital anomaly was noted in these cases. Logistic regression analysis showed that old age, high damage index at the initiation of IVCYC pulse therapy and high cumulative dosage of IVCYC were the independent risk factors of ovarian failure, and that the presence of amenorrhea, regardless of its duration, was the risk factor of pregnancy failure. Pregnancy was possible with a favorable outcome after the withdrawal of IVCYC pulse therapy, unless amenorrhea develops.

Keywords

amenorrhea cyclophosphamide lupus nephritis ovarian failure pregnancy

Get full access to this article

View all access options for this article.

References

Moore MJ. Clinical pharmacokinetics of cyclophosphamide . Clin Pharmacokinet 1991; 20: 194-208 .

Fox DA , McCune WJ. Immunosuppressive drug therapy of systemic lupus erythematosus . Rheum Dis Clin North Am 1994; 20: 265-299 .

Hemendinger RA , Bloom SE. Selective mitomycin C and cyclophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo . Immunopharmacology 1996; 35: 71-82 .

Boumpas DT , Austin HA , Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet 1992; 340: 741-745 .

Illei GG , Austin HA , Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis . Ann Intern Med 2001; 135: 248-257 .

Neuwelt CM , Lacks S , Kaye BR , Ellman JB , Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus . Am J Med 1995; 98: 32-41 .

Boumpas DT , Barez S , Klippel JH , Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus . Ann Intern Med 1990; 112: 674-677 .

Van der Shoun YT , van der Graff Y , Steyerberg EW , Eijkemans JC , Banga JD. Age at menopause as a risk factor for cardiovascular morbidity . Lancet 1996; 347: 714-718 .

Cann CE , Martin MC , Genant HK , Jaffe RB. Decreased spinal mineral content in amenorrheic women . JAMA 1984; 251: 626-629 .

10.

Warne GL , Fairley KF , Hobbs JB , Martin FI. Cyclophosphamide-induced ovarian failure . N Engl J Med 1973; 289: 1159-1162 .

11.

Koyama H , Wada T , Nishizawa Y , Iwanaga T , Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer . Cancer 1977; 39: 1403-1409 .

12.

Schilsky RL , Sherins RJ , Hubbard SM , Wesley MN , Young RC , DeVita VT. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin’s disease . Am J Med 1981; 71: 552-556 .

13.

Boumpas DT , Austin HA , Vaughan EM , Yarboro CH , Klippel JH , Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy . Ann Intern Med 1993; 119: 366-369 .

14.

McDermott EM , Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide . Ann Rheum Dis 1996; 55: 224-229 .

15.

Mok CC , Lau CS , Wong RWS. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy . Arthritis Rheum 1998; 41: 831-837 .

16.

Huong DLT , Amoura Z , Duhaut P et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients . J Rheumatol 2002; 29: 2571-2576 .

17.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter] . Arthritis Rheum 1997; 40: 1725-1725 .

18.

Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prongnosis Studies in SLE . Arthritis Rheum 1992; 35: 630-640 .

19.

Gladman D , Ginzler E , Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus . Arthritis Rheum 1996; 39: 363-369 .

20.

Houssiau FA , Vasconcelos C , D’Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide . Arthritis Rheum 2002; 46: 2121-2131 .

21.

Blumenfeld Z , Shapiro D , Shteinberg M , Avivi I , Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy . Lupus 2000; 9: 401-405 .

22.

Bermas BL , Hill JA. Effects of immunosuppressive drugs during pregnancy . Arthritis Rheum 1995; 38: 1722-1732 .

23.

Francis BM , Rogers JM , Sulik KK et al. Cyclophosphamide teratogenesis: evidence for compensatory responses to induced cellular toxicity . Teratology 1990; 42: 473-482 .

24.

Sanders JE , Hawley J , Levy W et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation . Blood 1996; 87: 3045-3052 .